| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f19b9a711398eecbe5238d5c692e6e2e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4418
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4418
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4422 |
| filingDate |
2013-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37e64c788980810844ddad9c878e72ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_030e818bf7687e183c376b95c87bd457
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3019990cc6c2414f90a7d14207ed4b2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d23a39e50c5e782952186a82db042486 |
| publicationDate |
2015-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20150104084-A |
| titleOfInvention |
Methods for controlling blood pressure and reducing dyspnea in heart failure |
| abstract |
The present invention is a method for treating, preventing, or alleviating symptoms such as dyspnea and / or methods for controlling, maintaining or reducing blood pressure in a patient suffering from acute heart failure or susceptible to acute heart failure. The present methods include the administration of an effective amount of a pharmaceutical composition containing a short acting dihydropyridine compound, such as clevidipine. The pharmaceutical composition may be administered as an initiator and if the blood pressure is not controlled or maintained within the target blood pressure range or is not reduced to within the target blood pressure range, the starting dose may be titrated to achieve blood pressure within the target blood pressure range have. The patient may have a shrinking blood pressure of about 120 mmHg or more. |
| priorityDate |
2012-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |